MannKind Receives $30.6 Million From Sanofi
January 09 2017 - 9:00AM
MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD)
today confirmed that it received $30.6 million from Sanofi on
January 6, 2017, representing the balance of the accelerated
insulin “put” option previously exercised by MannKind. This
payment was made pursuant to a previously disclosed agreement
reached with Sanofi on November 9, 2016.
About MannKind Corporation
MannKind Corporation (NASDAQ:MNKD)
(TASE:MNKD) focuses on the discovery, development and
commercialization of therapeutic products for patients with
diseases such as diabetes. MannKind maintains a website at
http://www.mannkindcorp.com to which MannKind regularly posts
copies of its press releases as well as additional information
about MannKind. Interested persons can subscribe on the MannKind
website to e-mail alerts that are sent automatically when MannKind
issues press releases, files its reports with the Securities and
Exchange Commission or posts certain other information to the
website.
Company Contact:
Rose Alinaya
SVP, Finance
661-775-5300
ralinaya@mannkindcorp.com
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Aug 2024 to Sep 2024
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Sep 2023 to Sep 2024